Fractional Erbium-doped Yttrium Aluminum Garnet Laser-assisted Drug Delivery of Hydroquinone in the Treatment of Melasma

Overview

Journal Clin Cosmet Investig Dermatol

Publisher Dove Medical Press

Specialty Dermatology

Date 2018 Jan 31

PMID 29379308

Citations 11

Authors

Ashraf M Badawi

Mai Abdelraouf Osman

Affiliations

Soon will be listed here.

Abstract

Background: Melasma is a difficult-to-treat hyperpigmentary disorder. Ablative fractional laser (AFL)-assisted delivery of topically applied drugs to varied targets in the skin has been an area of ongoing study and research.

Objective: The objective of this study was to evaluate the efficacy and safety of fractional erbium-doped yttrium aluminum garnet (Er:YAG) laser as an assisted drug delivery for enhancing topical hydroquinone (HQ) permeation into the skin of melasma patients.

Patients And Methods: Thirty female patients with bilateral melasma were randomly treated in a split-face controlled manner with a fractional Er:YAG laser followed by 4% HQ cream on one side and 4% HQ cream alone on the other side. All patients received six laser sessions with a 2-week interval. The efficacy of treatments was determined through photographs, dermoscopic photomicrographs and Melasma Area Severity Index (MASI) score, all performed at baseline and at 12 weeks of starting therapy. The patient's level of satisfaction was also recorded.

Results: Er:YAG laser + HQ showed significantly better results (<0.005) with regard to decrease in the degree of pigmentation as assessed on the 4-point scale than HQ alone. There was a significant decrease in MASI scores on Er:YAG laser + HQ side vs HQ side. Minor reversible side effects were observed on both sides.

Conclusion: AFL-assisted delivery of HQ is a safe and effective method for the treatment of melasma.

Citing Articles

Laser-mediated Solutions: Breaking Barriers in Transdermal Drug Delivery.

Haghsay Khashechi E, Afaghmehr A, Heydari N, Barfar A, Shokri J AAPS PharmSciTech. 2024; 25(6):142.

PMID: 38898170 DOI: 10.1208/s12249-024-02849-z.

Efficacy and Safety of Ablative Fractional Laser in Melasma: A Meta-analysis and Systematic Review.

Zhao S, Wang M, Lai X, Yan Y Lasers Med Sci. 2024; 39(1):71.

PMID: 38379033 DOI: 10.1007/s10103-024-03972-w.

Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events.

Ng W, Smith S Pharmaceutics. 2022; 14(12).

PMID: 36559233 PMC: 9787022. DOI: 10.3390/pharmaceutics14122738.

Laser microporation facilitates topical drug delivery: a comprehensive review about preclinical development and clinical application.

Zhao Y, Voyer J, Li Y, Kang X, Chen X Expert Opin Drug Deliv. 2022; 20(1):31-54.

PMID: 36519356 PMC: 9825102. DOI: 10.1080/17425247.2023.2152002.

CO fractional laser-assisted transdermal delivery of silk nanofiber carriers in a rabbit ear hypertrophic scar model.

Yang Y, Liu L, Wu X, Wang X, Lu Q, Zhang Z Burns Trauma. 2022; 10:tkac040.

PMID: 36380852 PMC: 9650785. DOI: 10.1093/burnst/tkac040.

References

Waibel J, Beer K, Narurkar V, Alster T . Preliminary observations on fractional ablative resurfacing devices: clinical impressions. J Drugs Dermatol. 2009; 8(5):481-5. View

Pandya A, Guevara I . Disorders of hyperpigmentation. Dermatol Clin. 2000; 18(1):91-8, ix. DOI: 10.1016/s0733-8635(05)70150-9. View

Guevara I, Pandya A . Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol. 2003; 42(12):966-72. DOI: 10.1111/j.1365-4632.2003.02017.x. View

Brightman L, Brauer J, Anolik R, Weiss E, Karen J, Chapas A . Ablative and fractional ablative lasers. Dermatol Clin. 2009; 27(4):479-89, vi-vii. DOI: 10.1016/j.det.2009.08.009. View

Grimes P . Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995; 131(12):1453-7. DOI: 10.1001/archderm.131.12.1453. View

Ma G, Wu P, Lin X, Chen H, Hu X, Jin Y . Fractional carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: a pilot study. Pediatr Dermatol. 2014; 31(3):286-91. DOI: 10.1111/pde.12299. View

Paasch U, Haedersdal M . Laser systems for ablative fractional resurfacing. Expert Rev Med Devices. 2010; 8(1):67-83. DOI: 10.1586/erd.10.74. View

Cavalie M, Sillard L, Montaudie H, Bahadoran P, Lacour J, Passeron T . Treatment of keloids with laser-assisted topical steroid delivery: a retrospective study of 23 cases. Dermatol Ther. 2014; 28(2):74-8. DOI: 10.1111/dth.12187. View

Attwa E, Khater M, Assaf M, Haleem M . Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study. Int J Dermatol. 2014; 54(2):235-44. DOI: 10.1111/ijd.12477. View

10.

Ortonne J, Passeron T . Melanin pigmentary disorders: treatment update. Dermatol Clin. 2005; 23(2):209-26. DOI: 10.1016/j.det.2005.01.001. View

11.

Alexiades-Armenakas M, Dover J, Arndt K . The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008; 58(5):719-37. DOI: 10.1016/j.jaad.2008.01.003. View

12.

Budamakuntla L, Loganathan E, Suresh D, Shanmugam S, Suryanarayan S, Dongare A . A Randomised, Open-label, Comparative Study of Tranexamic Acid Microinjections and Tranexamic Acid with Microneedling in Patients with Melasma. J Cutan Aesthet Surg. 2013; 6(3):139-43. PMC: 3800287. DOI: 10.4103/0974-2077.118403. View

13.

Baron E, Harris L, Redpath W, Shapiro H, Hetzel F, Morley G . Laser-assisted penetration of topical anesthetic in adults. Arch Dermatol. 2003; 139(10):1288-90. DOI: 10.1001/archderm.139.10.1288. View

14.

Lee W, Shen S, Al-Suwayeh S, Yang H, Yuan C, Fang J . Laser-assisted topical drug delivery by using a low-fluence fractional laser: imiquimod and macromolecules. J Control Release. 2011; 153(3):240-8. DOI: 10.1016/j.jconrel.2011.03.015. View

15.

Elias P, Menon G . Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res. 1991; 24:1-26. DOI: 10.1016/b978-0-12-024924-4.50005-5. View

16.

Lee W, Shen S, Kuo-Hsien W, Hu C, Fang J . Lasers and microdermabrasion enhance and control topical delivery of vitamin C. J Invest Dermatol. 2004; 121(5):1118-25. DOI: 10.1046/j.1523-1747.2003.12537.x. View

17.

Rajaratnam R, Halpern J, Salim A, Emmett C . Interventions for melasma. Cochrane Database Syst Rev. 2010; (7):CD003583. DOI: 10.1002/14651858.CD003583.pub2. View

18.

Erlendsson A, Anderson R, Manstein D, Waibel J . Developing technology: ablative fractional lasers enhance topical drug delivery. Dermatol Surg. 2014; 40 Suppl 12:S142-6. DOI: 10.1097/DSS.0000000000000207. View

19.

Hsiao C, Huang C, Hu S, Ko Y, Sung H, Chen C . Fractional carbon dioxide laser treatment to enhance skin permeation of ascorbic acid 2-glucoside with minimal skin disruption. Dermatol Surg. 2012; 38(8):1284-93. DOI: 10.1111/j.1524-4725.2012.02454.x. View

20.

Haedersdal M, Sakamoto F, Farinelli W, Doukas A, Tam J, Anderson R . Fractional CO(2) laser-assisted drug delivery. Lasers Surg Med. 2010; 42(2):113-22. DOI: 10.1002/lsm.20860. View